natgillin/translations-raw huggingface dataset:
A further 279 patients were treated with vedolizumab at Week 0 and Week 2 and then with placebo for up to 52 weeks.
Nadaljnjih 279 bolnikov je bilo zdravljenih z vedolizumabom na 0. teden in 2. teden in nato s placebom do 52 tednov.
A further multinational double-blind study (SP889) was conducted in 287 patients with early or advanced stages of Parkinson’s disease who had unsatisfactory early morning motor symptom control.
Naslednja večnacionalna dvojno slepa študija (SP889) je bila opravljena z 287 bolniki v zgodnji ali napredovali fazi Parkinsonove bolezni, ki so imeli zgodaj zjutraj nezadovoljivo kontrolo nad motoriko.
A further multinational double-blind study (SP889) was conducted in 287 patients with early or advanced stages of Parkinson’s disease who had unsatisfactory early morning motor symptom control.
Naslednja večnacionalna dvojno slepa študija (SP889)je bila opravljena z 287 bolniki v zgodnji ali napredovali fazi Parkinsonove bolezni, ki so imeli zgodaj zjutraj nezadovoljivo kontrolo nad motoriko.
A further study involving 519 patients compared Sprycel with imatinib in treating newly diagnosed Ph+ patients with chronic phase CML who had not received any previous treatment.
V dodatni študiji, ki je vključevala 519 bolnikov, so zdravilo Sprycel pri zdravljenju bolnikov, pri katerih so na novo ugotovili KML v kroničnem obdobju s prisotnim kromosomom Philadelphia in se pred tem še niso zdravili, primerjali z imatinibom.
A further study looked at the effects of Abseamed given under the skin in 416 patients with chronic kidney failure.
V nadaljnji študiji so proučevali učinke injiciranja zdravila Abseamed v veno pri 416 bolnikih s kronično odpovedjo ledvic.
A further study looked at the effects of Binocrit given under the skin in 416 patients with chronic kidney failure.
V nadaljnji študiji so proučevali učinke injiciranja zdravila Binocrit v veno pri 416 bolnikih s kronično odpovedjo ledvic.
A further study looked at the effects of Epoetin Alfa Hexal given under the skin in 416 patients with chronic kidney failure.
V nadaljnji študiji so proučevali učinke injiciranja zdravila Epoetin Alfa Hexal v veno pri 416 bolnikih s kronično odpovedjo ledvic.
A further study will also be carried out to confirm the most appropriate dose.
Prav tako bo izvedena dodatna študija, s katero bodo potrdili najprimernejši odmerek.
A further three studies compared the effectiveness of Parareg and placebo in a total of 136 patients with primary hyperparathyroidism over up to a year.
V nadaljnjih treh študijah so v času do enega leta primerjali učinkovitost zdravila Parareg z učinkovitostjo placeba pri skupno 136 bolnikih s primarnim hiperparatiroidizmom.
a gas cylinder whose valve is not protected by a cap or a shell should not be used a specific connection, with a 30 mm thread which is designated for medical use, complying with ISO 5145 and a pressure regulator which admits a pressure at least equal to 1.5 the maximum operating pressure (155 bar) of the gas cylinder should be used
jeklenke ne uporabljajte, če ventil ni zaščiten z zaporko ali plaščem uporabljajte specifično povezavo s 30-milimetrskim navojem za uporabo v medicinske namene, skladnim s standardom ISO 5145, in regulator tlaka, ki dopušča tlak vsaj do 150 % največjega obratovalnega tlaka jeklenke (155 bar)
A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur.
V redkih primerih, kjer se pojavijo utrujenost, glavobol, navzea in bruhanje, je treba pomisliti na splošen nezadosten učinek glukokortikosteroidov.
A generally greater effect of Simponi 50 mg + MTX versus MTX alone was demonstrated in the indicated population compared with the overall population.
Na splošno se je pokazal večji učinek zdravila Simponi 50 mg z metotreksatom v primerjavi s samim metotreksatom pri navedeni populaciji v primerjavi s celotno populacijo.
A genetic variant near the gene encoding interferon-lambda-3 (IL28B rs12979860, a C to T change) is a strong predictor of response to peginterferon alfa–2b/ribavirin.
Genetska varianta v bližini gena, ki kodira interferon-lambda-3 (IL28B rs12979860, sprememba iz C v T), je močan napovednik odziva na peginterferon alfa-2b/ribavirin.
a Genotypic sensitivity scores are calculated by summing up drug susceptibility values (1 = sensitive; 0 = reduced susceptibility) on all drugs in the baseline background regimen.
a Rezultati genotipske občutljivosti so izračunani s seštetjem vrednosti občutljivosti na zdravilo (1 = občutljivost; 0 = zmanjšana občutljivost) na vsa zdravila v osnovnem režimu zdravljenja.
A gentle massage of the site - while still maintaining pressure - helps disperse the Fertavid solution and relieve any discomfort.
To bo pripomoglo k hitrejši razporeditvi raztopine zdravila Fertavid in bo zmanjšalo neprijeten občutek.
A gentle massage of the site - while still maintaining pressure - helps disperse the Puregon solution and relieve any discomfort.
To bo pripomoglo k hitrejši razporeditvi raztopine zdravila Puregon in bo zmanjšalo neprijeten občutek.
a gestational age from 24 until 33 completed weeks a normal foetal heart rate
gestacijsko starostjo od 24 do 33 dopolnjenih tednov normalno srčno frekvenco ploda
a gestational age from 24 until 33 completed weeks a normal foetal heart rate
gestacijsko starostjo od 24 do 33 dopolnjenih tednov; normalno srčno frekvenco ploda.
A Getting ready
Priprava
A glass or cup
kozarec ali skodelica
A glass vial of 3 ml containing the adjuvanted liquid, with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
3 mililitrska steklena viala, ki vsebuje tekočino z dodatki, z zamaškom iz butil elastomera, premera 13 mm, ter je zaprta z aluminijasto zaporko.
A glass vial of 3 ml with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
3 mililitrska steklena viala z zamaškom iz butil elastomera, premera 13 mm, ter komplet z aluminijasto kapsulo.
A glass vial of 3 ml with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
Steklena viala 3 mililitrska z zamaškom iz butil elastomera, premera 13 mm ter zaprta z aluminijasto zaporko.
A glass with a little water or a spoon should be held below the nozzle and the dosing pump head has to be pushed down in a firm but calm and steady manner (not too slowly) right down to the stop (fig.
Pod cevnim izvodilom pridržimo kozarec z malo vode ali žlico; odmerno črpalko pritiskamo navzdol odločno, a mirno in enekomerno (ne prepočasi), vse dokler se ne zaustavi (sl.7, sl.
A glass with a little water or a spoon should be hold below the nozzle and the dosing pump head has to be pushed down in a firm but calm and steady manner (not too slowly) right down to the stop (fig.
Pod cevnim izvodilom pridržimo kozarec z malo vode ali žlico; odmerno črpalko pritiskamo navzdol odločno, a mirno in enekomerno (ne prepočasi), vse dokler se ne zaustavi (sl.7, sl.
A good immune response is reliant on a fully competent immune system.
Dober imunski odziv je odvisen od kompetentnega imunskega sistema.
A good place is a clean table or kitchen surface
Primerna površina je čista miza ali kuhinjska površina
A good place is a clean table or surface.
Primerna površina je čista miza ali površina.
a gp100 peptide vaccine is an experimental control.
a Peptidno cepivo gp100 je eksperimentalna kontrola.
A gradual dose increase of atorvastatin may be tailored to the clinical response.
Glede na klinični odziv bolnika, lahko odmerek atorvastatina postopoma zvečate.
A gradual dose increase of atorvastatin may be tailored to the clinical response.
Glede na klinični odziv bolnika, lahko odmerek atorvastatina postopoma zvišate.
A gradual resolution of the local reactions occurs, but in 20–30% of the animals these may persist for more than 42 days.
Lokalna reakcija postopno izgine, vendar pri 20-30 % živalih lahko ta ostane več kot 42 dni.
A graduated oral syringe is also included.
Priložena je tudi brizga za peroralno dajanje z oznakami količine.
A granules formulation of tenofovir disoproxil fumarate is available for patients having difficulty in swallowing film-coated tablets.
Formulacija dizoproksiltenofovirijev fumarata v obliki zrnc je na voljo za bolnike s težavami s pogoltnjenjem filmsko obloženih tablet.
A greater frequency of pulmonary embolism, infections (predominantly of dermatologic origin), diarrhoea, electrolyte imbalances, nausea, vomiting and dehydration was also observed in the treatment arms using Vectibix in combination with bevacizumab and chemotherapy.
V terapevtskih krakih z zdravilom Vectibix, uporabljenim v kombinaciji z bevacizumabom in kemoterapijo, so bile pogostejše tudi pljučna embolija, okužbe (pretežno dermatološkega izvora), driska, neravnovesje elektrolitov, navzea, bruhanje in dehidracija.
A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2)
V kratkoročnih študijah pri bolnikih mladostnikih so poročali o večjem obsegu povečanja telesne mase, spremembah lipidov in prolaktina, kot v študijah pri odraslih bolnikih (glejte poglavja 4.4, 4.8, 5.1 in 5.2).
A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs.
V (združeni) skupini, ki se je zdravila z infliksimabom, so pri večjem odstotku bolnikov lahko ukinili kortikosteroide ob ohranjeni klinični remisiji kot pri skupini, ki je prejemala placebo, kar velja tako za
A greater proportion of patients on eltrombopag did not require any antiviral dose reduction as compared to placebo (45% versus 27%).
Večji delež bolnikov, ki so prejemali eltrombopag, ni potrebovalo zmanjšanja odmerka protivirusnega zdravila glede na placebo (45 % v primerjavi s 27 %).
A greater proportion of patients treated with empagliflozin and with a baseline HbA1c ≥7.0% achieved a target HbA1c of <7% compared to placebo (Table 6).
V primerjavi s placebom je večji delež bolnikov, zdravljenih z empagliflozinom in z izhodiščno vrednostjo HbA1c ≥ 7,0 %, dosegel ciljno vrednost HbA1c < 7 % (preglednica 6).
A greater than dose-proportional increase in nelfinavir plasma concentrations was observed after single doses; however, this was not observed after multiple dosing.
Večji porast koncentracij nelfinavirja v plazmi glede na pričakovano raven so opazili po enkratnih odmerkih, pri večkratnem odmerjanju pa ne.
A greater than dose–proportional increase in indinavir plasma concentrations was observed over the 200 – 800 mg dose range.
Pri odmerkih med 200 in 800 mg so opazili večje plazemske koncentracije, kot bi bilo to sorazmerno z odmerkom.
a group of metabolic complications occurring after cancer treatment characterised by high blood levels of potassium and phosphate, and low blood levels of calcium (tumour lysis syndrome).
kupek presnovnih zapletov, ki se pojavijo po zdravljenju raka, za katere so značilne visoke vrednosti kalija in fosfata v krvi ter nizke vrednosti kalcija v krvi (sindrom tumorske lize)
A group of symptoms caused by a serious infection of the brain including:
Skupina simptomov, ki jih povzroča resna okužba možganov, vključno z/s:
a group of symptoms due to cancer in the body such as high blood levels of calcium and cholesterol, and low blood levels of sugar (paraneoplastic syndrome)
kupek simptomov, ki so posledica delovanja tumorja na telo, kot so visoke vrednosti kalcija in holesterola v krvi ter nizke vrednosti krvnega sladkorja (paraneoplastični sindrom)
A half-life time of 7.7 hours has been observed.
Razpolovni čas izločanja je 3,1 ura po dajanju..
A hard lump and warmth at the injection site
trda bula na mestu injiciranja in toplo mesto injiciranja,
a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease free survival compared to FAC.
razmerje ogroženosti Vrednost (TAC/FAC) manj kot 1 pomeni, da je kombinacija TAC povezana z daljšim preživetjem brez bolezni kot kombinacija FAC.
A hazard ratio < 1 indicates an advantage for BR-CAP.
Stopnja tveganja < 1 predstavlja prednost za skupino BzR-CAP.
A hazard ratio < 1 indicates an advantage for BzmbR-CAP.
Razmerje tveganja < 1 predstavlja prednost za skupino BzmbR-CAP.
A hazard ratio < 1 indicates an advantage for BzR-CAP.
Stopnja tveganja < 1 predstavlja prednost za skupino BzR-CAP.
a Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified by bisphosphonate use, number of bone metastases, and primary Gleason grade. b Hazard ratio based on the unadjusted Cox Model. c p-value based on a log-rank test.
a Razmerje tveganja in vrednost p na podlagi Coxovega modela, prilagojenega za PSA (ln) in LDH (ln) in stratificiranega glede na uporabo bisfosfonata, število metastaz v kosteh in primarni rezultat po Gleasonu. b Razmerje tveganja na podlagi neprilagojenega Coxovega modela. c vrednost p na podlagi testa log-rank.
A hazard ratio less than 1 indicates an advantage for VMP
Razmerje tveganja, manjše kot 1, kaže prednost zdravljenja z VMP.
A hazard ratio less than 1 indicates an advantage for VMP
Stopnja tveganja manjš
A hazard ratio less than 1 indicates an advantage for VMP
Stopnja tveganja manjša kot 1 kaže prednost zdravljenja z VMP.
A hazard ratio of less than 1 favors docetaxel + cisplatin + 5-FU
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU
A hazard ratio of less than 1 favors docetaxel + cisplatin + 5-FU
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU.
A hazard ratio of less than 1 favors docetaxel + cisplatin + fluorouracil
Razmerje ogroženosti manj kot 1 pomeni prednost kombinacije docetaksel + cisplatin + fluorouracil
A hazard ratio of less than 1 favors docetaxel + cisplatin + fluorouracil
Razmerje ogroženosti manj kot 1 pomeni prednost kombinacije docetaksel + cisplatin + fluorouracil.
A hazard ratio of less than 1 favors Docetaxel +Cisplatin+5-FU
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU.
A hazard ratio of less than 1 favours docetaxel + cisplatin + fluorouracil
Razmerje ogroženosti manj kot 1 pomeni prednost kombinacije docetaksel + cisplatin + fluorouracil.
A Hazard ratio of less than 1 favours docetaxel + cisplatin + fluorouracil
Razmerje ogroženosti manj kot 1 pomeni prednost kombinacije docetaksel + cisplatin +fluorouracil
a head injury
poškodbo glave,
a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels
rčni napad ali katero koli drugo bolezen srca, vključno z srčnimi aritmijami, ali bolezni ožilja;
a heart attack within the last six months,
rčni napad v zadnjih šestih mesecih,
a heart attack, heart beat problems, circulation or breathing problems
rčna kap, težave z bitjem srca, težave s krvnim obtokom ali dihanjem;
a heart attack, or unstable angina (angina or chest pain that is not well controlled).
rčni infarkt ali nestabilno angino pektoris (angina pektoris ali bolečina v prsih, ki ni dobro urejena).
a heart attack, or unstable angina (angina or chest pain that is not well controlled).
rčni infarkt ali nestabilno angino pektoris (tj. bolečino v prsih, ki ni dobro obvladana).
a Heart rate less than 60 beats per minutes (bpm) b Permanently discontinue in the event of recurrence.
a srčna frekvenca manj kot 60 utripov na minuto b Če se težave ponovijo, je treba zdravilo dokončno ukiniti.
a heart rhythm disorder, abnormal pulse
motnja srčnega ritma, nenormalen srčni utrip
a heart rhythm problem called ‘bundle branch block’
težava s srčnim ritmom, imenovana kračni blok,
a heart rhythm problem called ‘bundle branch block’
težava s srčnim ritmom, imenovana »kračni blok«,
a heart rhythm problem called ‘“bundle branch block”’
težava s srčnim ritmom, imenovana kračni blok,
a herbal medicine, used to treat depression.
zeliščno zdravilo, ki se uporablja za zdravljenje depresije.
a hernia of the tube that carries food to your stomach low haemoglobin or red blood cell count (anaemia)
hernija v predelu, ki prinaša hrano v vaš želodec nizek hemoglobin ali nizko število rdečih krvnih celic (anemija)
A heterologous booster vaccination with a 7.5 µg non-adjuvanted formulation of the A/Indonesia/05/2005 strain vaccine has been administered 12 months after a priming vaccination with two doses of the A/Vietnam/1203/2004 strain vaccine in children and adolescents aged 9 to 17 years (N=196), children aged 3 to 8 years (N=79) and infants and children aged 6 months to 35 months (N=25).
Poživitveno cepljenje s 7,5 µg heterolognega cepilnega seva A/Indonesia/05/2005 brez adjuvansa je bilo uporabljeno pri otrocih in mladostnikih, starih od 9 do 17 let (N=196), pri otrocih, starih od 3 do 8 let (N=79), ter dojenčkih in otrocih, starih od 6 do 35 mesecev (N=25), 12 mesecev po primarnem cepljenju z dvema odmerkoma cepiva s sevom A/Vietnam/1203/2004.
A high fat, high-calorie meal resulted in 19% higher exposure compared to overnight fasting.
Obrok zelo mastne, visoko kalorične hrane je povzročil 19 % večjo izpostavljenost v primerjavi z dajanjem zdravila zjutraj, na tešče.
a high level of alkaline phosphatase in your blood
visoka koncentracija alkalne fosfataze v krvi,
a high level of alkaline phosphatase in your blood
visoka koncentracija alkalne fosfataze v krvi;
a high level of fat in your blood (triglycerides) fluid retention due to cardiac or kidney problems
zvišane ravni maščob (trigliceridov) v krvi; zastajanje tekočine v telesu zaradi težav s srcem ali ledvicami.
A high number of circulating lymphocytes (> 400,000/mcL) may confer increased risk.
Veliko število cirkulirajočih limfocitov (> 400.000/mikroliter) lahko pomeni povečano tveganje.
A high proportion of patients (approximately 62%) went on to receive a variety of non-protocol specified anti- cancer therapies, which may have impacted the analysis of overall survival.
Velik del bolnikov (približno 62 %) je prejemal različna zdravila za zdravljenje novotvorb, ki niso bila določena v protokolu študije, kar je lahko vplivalo na analizo celokupnega preživetja.
A high proportion of patients (approximately 63% IFN/placebo; 55% Avastin/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Visok delež bolnikov (približno 63 % interferon/placebo; 55 % Avastin/placebo) je po zaključku študije prejemal različna nespecificirana zdravljenja novotvorb, vključno z antineoplastičnimi zdravili, kar je lahko imelo vpliv na analizo celokupnega preživetja.
A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
Veliko tveganje za arterijsko trombembolijo zaradi večih dejavnikov tveganja (glejte poglavje 4.4) ali prisotnosti enega resnega dejavnika tveganja, kot je:
A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
Visoko tveganje arterijske trombembolije zaradi več dejavnikov tveganja (glejte poglavje 4.4) ali prisotnosti katerega od resnih dejavnikov tveganja, kot so:
A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4).
Veliko tveganje za vensko trombembolijo zaradi prisotnosti večih dejavnikov tveganja (glejte poglavje 4.4).
A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4);
Višje tveganje za vensko trombembolijo zaradi prisotnosti več dejavnikov tveganja (glejte poglavje 4.4)
a high temperature (fever)
povišano telesno temperaturo (vročina)
a high temperature (fever)
visoko temperaturo (vročino),
A high-fat, high-calorie meal delays the absorption of levodopa by two hours.
Obroki, bogati z maščobami, ali zelo kalorični obroki povzročijo zakasnitev absorpcije levodope za dve uri.
A higher dose of fluconazole may be
Mogoče bo potreben večji odmerek teh
A higher dose of these antidepressants may
Mogoče bo potreben večji odmerek teh
A higher dose of these proton pump
Mogoče bo potreben večji odmerek teh
A higher dose of umeclidinium/vilanterol (113/22 micrograms) was also studied in a 24-week placebo controlled clinical study and in two of the three 24-week active-controlled studies.
Višji odmerek kombinacije umeklidinij/vilanterol (113/22 mikrogramov) so prav tako preučili v 24-tedenski klinični študiji, kontrolirani s placebom, in v dveh od treh 24-tedenskih študij, kontroliranih z zdravilno učinkovino.
A higher frequency of adverse reactions (e.g., dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is co-administered with ritonavir dosed as an antiretroviral agent.
Med sočasno uporabo efavirenza z ritonavirjem, odmerjanim kot protiretrovirusnim zdravilom, so opažali večjo pogostnost neželenih učinkov (npr. omotico, navzejo, parestezije) in laboratorijskih nepravilnosti (zvišanje jetrnih encimov).
A higher frequency of adverse reactions (eg, dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is co-administered with ritonavir dosed as an antiretroviral agent.
Med sočasno uporabo efavirenza z ritonavirjem, odmerjanim kot protiretrovirusnim zdravilom, so opažali večjo pogostnost neželenih učinkov (npr. omotico, navzejo, parestezije) in laboratorijskih nepravilnosti (zvišanje jetrnih encimov).
A higher incidence has been observed in patients of Japanese origin (see section 4.4)
Pri bolnikih japonskega porekla so opazili višjo incidenco (glejte poglavje 4.4).
A higher incidence has been observed in patients of Japanese origin (see section 4.4).
Pri bolnikih japonskega porekla so opazili višjo incidenco (glejte poglavje 4.4).
A higher incidence of hand foot skin reaction (HFSR) / palmar-plantar erythrodysesthesia syndrome, severe liver function test abnormalities and hepatic dysfunction was observed in Asian (in particular Japanese) patients treated with Stivarga compared with Caucasians.
Večjo incidenco kožne reakcije na dlaneh in podplatih (HFSR - hand-foot skin reaction) ali sindroma palmarno-plantarne eritrodisestezije, resne nenormalnosti v izvidih preiskav delovanja jeter in moteno delovanje jeter so opazili pri bolnikih azijske rase (predvsem pri Japoncih), zdravljenih z zdravilom Stivarga v primerjavi z belci.
A higher incidence of ILD (approximately 5% with a mortality rate of 1.5%) is seen among patients with Japanese origin.
Pri bolnikih japonskega porekla so opazili višjo incidenco intersticijske bolezni pljuč (približno 5-%, z 1,5-% umrljivostjo).
A higher incidence of skin laceration may be attributable to more vigorous finger extension procedures in patients after receiving anesthesia to the hand.
Večjo incidenco raztrganja kože je mogoče pripisati bolj močnim postopkom iztegovanja prsta pri bolnikih, ki so prejeli anestezijo v roko.
A higher incidence of weight decrease, decreased appetite, headache and depression was observed during Study RO-2455-404-RD in patients receiving concomitant roflumilast and long-acting muscarinic antagonists (LAMA) plus concomitant inhaled corticosteroids (ICS) and long acting B2 agonists (LABA) compared to those treated only with concomitant roflumilast, ICS and LABA.
V študiji RO-2455-404-RD so pri bolnikih, ki so se sočasno zdravili z roflumilastom in dolgodelujočimi muskarinskimi antagonisti (LAMA) ter inhalacijskimi kortikosteroidi in dolgodelujočimi agonisti adrenergičnih receptorjev beta-2 (LABA), opazili večjo pojavnost zmanjšanja telesne mase, zmanjšanja apetita, glavobola in depresije v primerjavi z bolniki, ki so se sočasno zdravili le z roflumilastom, inhalacijskimi kortikosteroidi in LABA.
A higher incidence rate of hypoglycemia events was reported in patients with pNET in comparison to MRCC and GIST.
Pri bolnikih s pNET so v primerjavi z bolniki z MRCC in GIST poročali o večji incidenci hipoglikemije.